Both modified cognitive behavioral therapy (CBT) and pain education (EDU) interventions were associated with improved pain in patients with disadvantaged backgrounds.
Olanzapine and quetiapine have gained attention as adjuncts in pain management regimens.
A chart outlining the pharmacokinetics of atypical antipsychotics, including information on bioavailability, half-life and CYP 450 metabolism.
A chart with daily dose thresholds for antipsychotic medications.
In the past, clinicians believed anorexia arose from control battles with parents and that the individual had to develop insight and motivation to recover.
Early adherence is an especially problematic, significant and modifiable barrier to quality care for depression.
Over the long term, overweight and obese patients with type 2 diabetes often regain weight lost during weight loss programs.
Digital CBT is associated with reductions in insomnia, for university students.
ECT significantly reduced headache incidence and severity.
A chart outlining pharmacotherapies for ADHD, including information on form, strength, maximum dosages and administration.
Anxiolytic medications daily dose threshold chart.
In traditional acupuncture, a concept that is central to achieving a therapeutic response is De Qi, which represents the sensory effects induced by the procedure.
Research findings support continuation of ECT plus medication in a depressed elderly population.
Results of brain imaging studies demonstrate that "hypnosis influences all of the cortical areas and neurophysiological processes that underlie pain and emotions."
These preliminary findings suggest that combined treatment with MAAT and methylphenidate can improve attention, episodic and working memory, and executive functioning following traumatic brain injury.
The ADA released detailed guidelines for psychosocial assessments and care based on factors including age, type of diabetes, and family support system.
The major issues of drug development are that pre-clinical animal efficacy studies do not accurately predict human efficacy, and clinical trials often inaccurately fail to show drug efficacy.
A webinar on patient shame forms part of the Prescribers' Clinical Support System for Opioid Therapies.
Sunovion have announced positive results from a study evaluating Latuda (lurasidone HCI) for the treatment of schizophrenia in adolescents aged 13 to 17 years old.
The recovery time varies depending on which class of medication the patient is overusing.
Connectivity in the right midfrontal gyrus may help predict placebo response. This finding has widespread implications in drug development.
Hypopituitarism may be associated with reduced oxytocin concentrations and impaired empathic ability.
The crystal structure may provide inspiration for designing drugs that refine efficacy and avoid adverse events.
There was a significantly greater improvement in memantine group and a greater response rate at weeks 4 and 6.
Research found that cognitive rehabilitation program could improve self-reported cognitive function through 6 months.
Medications used to treat addiction cut the risk of reoffending in half.
Dr. Scott Zeller suggests it is time to move away from emergency intramuscular haloperidol.
One topic of criticism is the relative dearth of scientific evidence regarding the efficacy of 12-step programs.
Laughing about 10 minutes every day has similar benefits to eating vegetables, exercising, and meditating.
Dialectical behavioral therapy uses the concept of "radical acceptance" to help manage the psychological and emotional aspects of chronic pain.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Clinician Insight: Exploring the Link Between Bipolar Disorder and Binge Eating Disorder
- #MeToo: Helping Victims Cope With Sexual Harassment
- Association Between Psychosis and Development of Dementia in Older Men
- Psychosis Could Be a Potential Side Effect of Steroid Treatment in Kids
- Personality Functioning Associated With Global Functioning in Bipolar Disorder I
- Nutritional Influences on Bipolar Disorder in Children
- Triiodothyronine in the Treatment of Bipolar Depression
- Old Challenges and New Directions in Managing Tardive Dyskinesia
- Similar Rates of Childhood Trauma in Schizophrenia and Substance Use Disorders
- Potential for SERMs as Adjunctive Therapy for Schizophrenia
- Childhood Insulin Resistance Associated With Later Psychosis
- Lamotrigine Similar to Placebo in Treating Borderline Personality Disorder
- Glucocorticoids May Increase Risk of Developing Schizophrenia Spectrum Disorder
- Predictors, Incidence of Long-term Use of Benzodiazepines, Z-Drugs in Bipolar Disorder
- Cardiometabolic Dysregulation Associated With Cognitive Decline Mediated by Depression